GlassScriptPhysician profile
Leonardo Montemurro
NPI 1689620072
$2,239.99
in general payments reported to CMS, 2019-2025
28 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $343 · 2021: $197 · 2023: $15.63 · 2024: $265 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $474.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.92 | 2019-2025 | |
| Novo Nordisk INC | $239.40 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $156.48 | 2019-2020 | |
| Amgen INC. | $127.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.63 | 2019-2020 | |
| Lundbeck LLC | $96.68 | 2019-2025 | Rexulti |
| Heartflow, INC. | $85.45 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $71.61 | 2019 | |
| Lilly USA, LLC | $67.91 | 2019-2025 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.74 | 2025 | Caplyta |
| Boston Scientific Corporation | $41.41 | 2025 | Watchman Access System |
| Dexcom, INC. | $37.45 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $33.75 | 2020 | |
| Sanofi Pasteur INC. | $32.39 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.14 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $25.00 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $23.61 | 2025 | Zenpep |
| Mylan Specialty L.P. | $23.37 | 2020 | |
| Axsome Therapeutics, INC. | $20.93 | 2025 | Symbravo |
| Glaxosmithkline, LLC. | $20.57 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.00 | 2021 | |
| Merck Sharp & Dohme LLC | $18.53 | 2019 | |
| Astellas Pharma US INC | $18.42 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $18.24 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.48 | 2019 | |
| Radius Health, INC. | $15.30 | 2019 | |
| Shire North American Group INC | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonardo Montemurro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.